EA201591881A1 - Гетероциклическое соединение - Google Patents

Гетероциклическое соединение

Info

Publication number
EA201591881A1
EA201591881A1 EA201591881A EA201591881A EA201591881A1 EA 201591881 A1 EA201591881 A1 EA 201591881A1 EA 201591881 A EA201591881 A EA 201591881A EA 201591881 A EA201591881 A EA 201591881A EA 201591881 A1 EA201591881 A1 EA 201591881A1
Authority
EA
Eurasian Patent Office
Prior art keywords
salt
diseases
present
syndrome
heterocyclic compound
Prior art date
Application number
EA201591881A
Other languages
English (en)
Inventor
Масато Йосида
Хироюки Нагамия
Юсуке Охба
Масаки Сето
Такатоси Його
Сатоси Сасаки
Норихито Токунага
Казуйоси Асо
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA201591881A1 publication Critical patent/EA201591881A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Предлагается соединение или его соль, которое обладает высокой ингибирующей активностью в отношении JAK и которое применяется в качестве профилактического или терапевтического средства при аутоиммунных заболеваниях (ревматоидном артрите, псориазе, воспалительном заболевании кишечника, синдроме Шегрена, синдроме Бехчета, множественном склерозе, системной эритематозной волчанке и так далее), онкологических заболеваниях (лейкозе, лейомиосаркоме матки, раке предстательной железы, множественной миеломе, кахексии, миелофиброзе и так далее) и других подобных заболеваниях. Настоящее изобретение относится к соединению, представленному формулой (I)где каждый символ определен в описании настоящего изобретения, или к его соли.
EA201591881A 2013-03-28 2014-03-27 Гетероциклическое соединение EA201591881A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013070477 2013-03-28
PCT/JP2014/058999 WO2014157569A1 (ja) 2013-03-28 2014-03-27 複素環化合物

Publications (1)

Publication Number Publication Date
EA201591881A1 true EA201591881A1 (ru) 2016-04-29

Family

ID=51624525

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591881A EA201591881A1 (ru) 2013-03-28 2014-03-27 Гетероциклическое соединение

Country Status (9)

Country Link
US (2) US9637483B2 (ru)
EP (1) EP2980089B1 (ru)
JP (1) JPWO2014157569A1 (ru)
CN (1) CN105263932B (ru)
BR (1) BR112015024638A2 (ru)
CA (1) CA2907847A1 (ru)
EA (1) EA201591881A1 (ru)
ES (1) ES2661012T3 (ru)
WO (1) WO2014157569A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015024638A2 (pt) * 2013-03-28 2017-07-18 Takeda Pharmaceuticals Co composto, medicamento, métodos para inibir a janus cinase em um mamífero e para profilaxia ou tratamento de doença, e, uso do composto ou sal
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
WO2016168638A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
UY36630A (es) 2015-04-17 2016-11-30 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
WO2016168633A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
JP2020516672A (ja) * 2017-04-18 2020-06-11 セルジーン クオンティセル リサーチ，インク． 治療用化合物
CN108484609A (zh) * 2018-04-10 2018-09-04 中国药科大学 一种新颖的嘌呤类似物jak激酶抑制剂的制备与应用
CN108752277B (zh) * 2018-06-11 2020-11-24 浙江理工大学 一种1-(3-甲基-1-苯基-1h-吡唑-5-基)哌嗪的安全制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009308675A1 (en) * 2008-10-31 2010-05-06 Genentech, Inc. Pyrazolopyrimidine JAK inhibitor compounds and methods
TW201103904A (en) 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
AU2011240808B2 (en) 2010-04-14 2015-01-22 Array Biopharma Inc. 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases
TW201245155A (en) 2010-09-01 2012-11-16 Du Pont Fungicidal pyrazoles
CA2817785A1 (en) 2010-11-19 2012-05-24 Toby Blench Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors
CN104271574B (zh) 2012-02-20 2017-01-25 武田药品工业株式会社 杂环化合物
EP2857400A4 (en) 2012-06-01 2015-12-09 Takeda Pharmaceutical HETEROCYCLIC COMPOUND
BR112015024638A2 (pt) * 2013-03-28 2017-07-18 Takeda Pharmaceuticals Co composto, medicamento, métodos para inibir a janus cinase em um mamífero e para profilaxia ou tratamento de doença, e, uso do composto ou sal

Also Published As

Publication number Publication date
US9637483B2 (en) 2017-05-02
CN105263932B (zh) 2018-01-09
WO2014157569A1 (ja) 2014-10-02
EP2980089B1 (en) 2017-12-20
US20160039811A1 (en) 2016-02-11
CN105263932A (zh) 2016-01-20
EP2980089A4 (en) 2016-09-07
US20170174682A1 (en) 2017-06-22
ES2661012T3 (es) 2018-03-27
BR112015024638A2 (pt) 2017-07-18
CA2907847A1 (en) 2014-10-02
JPWO2014157569A1 (ja) 2017-02-16
EP2980089A1 (en) 2016-02-03

Similar Documents

Publication Publication Date Title
EA201591881A1 (ru) Гетероциклическое соединение
EA201492250A1 (ru) Гетероциклическое соединение
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
CY1125110T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
EA201890338A1 (ru) Оксадиазольные производные, пригодные в качестве ингибиторов hdac
EA201990833A1 (ru) Соединение пиридина
EA201590281A1 (ru) Новые гетероарильные и гетероциклические соединения, их композиции и способы
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
MA40076A (fr) Inhibiteurs de syk
EA201691442A1 (ru) N-азаспироциклоалканзамещенные n-гетероарильные соединения и композиции для ингибирования активности shp2
EA201290305A1 (ru) Производные трициклического пиразоламина
EA201790202A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
WO2014145015A3 (en) Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
MD4684B1 (ru) Составы на основе имидазопиразинов в качестве SYK ингибиторов
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
EA201700042A1 (ru) Соединения имидазопиридазина
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
EA201790206A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde4
MX349548B (es) Compuestos de tienopirimidina.
MX2017005422A (es) Inhibidores de histona desacetilasa y sus usos en terapia.
MX2015013936A (es) Compuestos de pirimidina condensada sustituida.